EMR-based Genetic Studies: The eMERGE Network
The Electronic Medical Records and Genomics (eMERGE) Network is funded by the National Human Genome Research Institute (NHGRI) to develop and implement approaches for leveraging biorepositories with electronic medical record (EMR) systems for large-scale genomic research, including genome-wide association studies (GWAS), sequencing and structural variation.
The five participating sites are Group Health Cooperative (with the University of Washington), Marshfield Clinic, Mayo Clinic, Northwestern University and Vanderbilt University. Each site is conducting a GWAS of a primary and supplementary phenotype.
The Mayo Clinic proposal aims to identify genetic loci associated with peripheral arterial disease and red blood cell traits, including hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration.
Phenotype characteristics and covariates relevant to statistical genetic analyses are derived using EMR-based algorithms, including diagnosis and procedure codes, laboratory data, medication use, and natural language processing of unstructured text. An ethical, legal and social issues (ELSI) component is included, which focuses in particular on community interaction and return of results.
Mayo eMERGE phase II project
As part of eMERGE-I, EMR-based algorithms were used to enable GWAS of several primary and network-wide phenotypes. In phase II of eMERGE (July 2011 to June 2015), the research infrastructure established in eMERGE-I is being leveraged to identify common genetic variants that influence medically important phenotypes.
The Mayo eMERGE-II cohort (6,916 people) includes the 3,769 eMERGE-I patients and an additional 3,147 individuals, the majority (90 percent) of whom were genotyped on the same Illumina 660W platform.
Mayo Clinic is working with other eMERGE-II sites to expand and validate the library of electronic phenotyping algorithms to enable GWAS of multiple phenotypes of interest. A major focus in phase II is to translate recent GWAS findings into clinical practice.
Specific aims are to:
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.